Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Nov 21, 2019 8:39pm
120 Views
Post# 30380568

RE:RE:RE:RE:RE:RE:RE:RE:RE:Investigate this company

RE:RE:RE:RE:RE:RE:RE:RE:RE:Investigate this company

I brought it up earlier. After a year the SEC requires Annual rsults within 60 days if I remember correctly. While I understand that they may want to consider not doing it this year, I would be disappointed if they wait all the way until the end of Febrary.

Sure, they may soften the blow of lacklustre results with positive FDA news, but why dilute the FDA news? Rip the bandaid off ad get earnings out in late Jan then really hit home the FDA news an potential growth opportunity on its own a month later. Conversely if the Earnings are good,then build some momentum in advance. 

That's my two cents, but would love to hear any insights you may have heard as to why it will be later in feb...


SPCEO1 wrote: They have indicated they will report later in February this year. quote=Wino115]Until such time they can talk about a better 4th quarter (hard not to beat last quarters slowdown), show some SV pickup or get FDA confirmation of anything, the share will drift.  You're probably fine for 30 days and I think your explanation makes sense. It's The problem with an illiquid small cap not really followed by analysts or many investors. 

Someone previously brought up that they may have a different reporting requirement this year given the SEC reporting.  In the past they waited until Feb to announce 4th Quarter and annual. I would need to check what the quarterly foreign issuer rules are.  But it may be before Feb.  I'm not up on those rules.  Guess we'll find out, but Dubuc should know if someone wants to lob an email in to him.


[/quote]
 

Bullboard Posts